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Abstract
Normal pregnancy is associated with a mild systemic inflammatory response and an immune bias towards type 2 cytokine
production, whereas pre-eclampsia is characterized by a more intense inflammatory response, associated with endothelial
dysfunction and a type 1 cytokine dominance. Interleukin (IL)-33 is a newly described member of the IL-1 family, which
binds its receptor ST2L to induce type 2 cytokines. A soluble variant of ST2 (sST2) acts as a decoy receptor to regulate the
activity of IL-33. In this study circulating IL-33 and sST2 were measured in each trimester of normal pregnancy and in
women with pre-eclampsia. While IL-33 did not change throughout normal pregnancy, or between non-pregnant, normal
pregnant or pre-eclamptic women, sST2 was significantly altered. sST2 was increased in the third trimester of normal
pregnancy (p,0.001) and was further increased in pre-eclampsia (p,0.001). This increase was seen prior to the onset of
disease (p,0.01). Pre-eclampsia is a disease caused by placental derived factors, and we show that IL-33 and ST2 can be
detected in lysates from both normal and pre-eclampsia placentas. ST2, but not IL-33, was identified on the
syncytiotrophoblast layer, whereas IL-33 was expressed on perivascular tissue. In an in vitro placental perfusion model,
sST2 was secreted by the placenta into the ‘maternal’ eluate, and placental explants treated with pro-inflammatory
cytokines or subjected to hypoxia/reperfusion injury release more sST2, suggesting the origin of at least some of the
increased amounts of circulating sST2 in pre-eclamptic women is the placenta. These results suggest that sST2 may play a
significant role in pregnancies complicated by pre-eclampsia and increased sST2 could contribute to the type 1 bias seen in
this disorder.
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Introduction
Pre-eclampsia is a common but complex disease which affects
2.5–3% of pregnancies and threatens the lives of both the mother
and baby. The maternal syndrome is driven by a dysfunctional
uteroplacental circulation and the release of pro-inflammatory
trophoblast derived factors [1], causing an excessive maternal
inflammatory response with associated endothelial dysfunction.
This results in new hypertension and proteinuria and other
features that characterise the disease [2]. Normal pregnancy is also
associated with a vascular inflammatory response secondary to the
presence of the placenta. It is not only of lower intensity but
characterized by a type 2 immune bias in contrast to the type 1
bias of pre-eclampsia.
One marker for type 2 immune bias is ST2L. ST2 is a member
of the IL-1 receptor super-family with four isoforms of which the
best characterised are ST2L, the membrane bound form, and an
alternatively spliced soluble ST2 (sST2) [3]. ST2L is expressed on
immune cells such as mast cells, macrophages and some
lymphocytes (NK cells and type 2 T helper cells) [4,5,6]. High
levels of sST2 mRNA are found in alveolar epithelium and
cardiac myocytes with lower levels in peripheral blood mononu-
clear cells and endothelium [7]. In venous and arterial endothelial
cells its expression is increased by pro-inflammatory stimuli
such as IL-1b, phorbol ester or TNF-a [8] and by activated Th2
cells [9].
IL-33 is the ligand for ST2 [10]. It is constitutively expressed in
the nuclei of endothelium of both large and small vessels [11] and
is widespread in mucosal epithelial surfaces, localised in cytoplasm
as well as the nucleus suggesting dual function [12]. As a soluble
factor it signals via ST2L and the IL-1Receptor accessory protein
(IL-1RAcP) and induces Type 2 cytokines such as IL-4, IL-5 and
IL-13 from immune cells [6,10].
IL-33 is released after cellular necrosis, and it belongs to a
family of molecules called ‘alarmins,’ which includes HMGB1 and
IL-1a, which also have dual nuclear and cytokine functions [13].
Full length IL-33 (33 kDa) can be cleaved by caspase-1 into a
shorter 18 kDa form, which is reported to be functionally inactive
[14,15]. In addition, secreted IL-33 function can be prevented by
sST2, which acts as a decoy receptor. Circulating IL-33 is elevated
in asthma, anaphylaxis, rheumatoid arthritis, inflammatory bowel
disease and sepsis [16,17,18,19]. Circulating sST2 is increased in
asthma, sepsis, autoimmune diseases such as systemic lupus
erythematosus, dyspnea and acute myocardial infarction
[17,20,21,22,23]. Increased circulating sST2 may have a negative
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mediated neutrophil recruitment to the site of infection in sepsis
[24], and is associated with poor survival after acute myocardial
infarction [25]. In the heart, ischaemia reperfusion injury and
infarction are moderated by IL-33 which protects cardiomyocytes
from apoptosis; the benefit is partially abolished by sST2 [26]. As
pre-eclampsia has a similar pathology [27], sST2 and IL-33 may
have a role in this disease, either as a primary cause or a
downstream player in the regulation of the systemic inflammatory
response. Maternal blood levels of IL-33 and sST2 have not
previously been investigated in pregnancy or pre-eclampsia. This
paper addresses these issues.
Materials and Methods
Subject recruitment and ethics statement
These studies were approved by the Oxfordshire Research
Ethics Committee and written consent was obtained from each
participant. Three study groups were recruited. To determine
changes in sST2 and IL-33 associated with pre-eclampsia, a single
blood sample (plasma samples were collected using EDTA
anticoagulation tubes) was taken from women with pre-eclampsia
(n=20) who were matched for age (+/24 years), parity (0, 1–3,
4+), and gestational age (+/213 days) to normal pregnant women,
and for age and parity to non-pregnant controls (Table 1). To
determine the changes with gestational age in circulating
concentrations of sST2 and IL-33, healthy women were recruited
to the Oxford Pregnancy Biobank in the first trimester of
pregnancy (11–13 weeks gestation), and further samples acquired
during the second (20–22 weeks) and third trimesters (30–34
weeks) (characteristics recorded in Table 2). 15 women became
pre-eclamptic, these were matched to normal pregnant women.
Additional samples were taken from 13/15 of the women who
developed pre-eclampsia when diagnosed. 5 of these 15 women
had developed pre-eclampsia prior to the third trimester sample
being taken. The other 10 women had a third trimester sample
taken on average 20 days (range 6–39 days) prior to diagnosis.
Blood samples from 15 matched, healthy, non-pregnant women
were also taken. Plasma samples were taken into sodium citrate
anti-coagulation tubes. Finally, to further study the effect of
gestational age on sST2 levels an additional 30 women with pre-
eclampsia were matched to normal pregnant women, therefore
totalling 50 matched cases of pre-eclampsia (Table 3).
Pre-eclampsia was defined as the new onset of a diastolic blood
pressure (BP) $90 mmHg on at least two occasions within
24 hours and new onset proteinuria $300 mg in a 24 hour urine
collection, 50 mg/mmol protein/creatinine ratio or at least 2+ on
dipstick testing on two consecutive measurements. All cases and
controls had singleton pregnancies with no known fetal abnor-
mality. Blood samples were collected, plasma and serum were
isolated and the samples stored at 280uC until analysis.
There were no significant differences in age, parity or gestation
in any of the groups. At the first trimester sample both systolic and
diastolic blood pressure was significantly increased in women
whose pregnancy was complicated by pre-eclampsia. It is well
recognized that increased blood pressure at booking is a risk factor
for the disease [28]. Case characteristics are detailed in tables 1, 2
and 3.
Detection of sST2 and IL-33 by ELISA
sST2 was measured in plasma using the PresageH ST2 Assay
(Critical Diagnostics, San Diego, USA) according to the
manufacturer’s instructions. IL-33 was measured in serum or
plasma using a human IL-33 ELISA kit with pre-coated plates
(BioLegend, San Diego, U.S.A.). We found that the same amount
of IL-33 is detected in plasma or serum samples from the same
individual (data not shown). For each assay both standards and
samples were tested in duplicate.
Detection of ST2 and IL-33 by immunohistochemistry
Tissue samples from normal (n=3) and pre-eclampsia
placentas (n=3) obtained after caesarean section were fixed in
10% formalin and processed into paraffin blocks. Serial sections
(5 mm) were cut on coated slides and dried. Slides were
deparaffinised in Histo-Clear (National Diagnostics, MERCK,
Eorulab S.A.), rehydrated in a graded alcohol series, and sodium
citrate antigen retrieval performed. Sections were pre-blocked
with 10% FCS/PBS for one hour at room temperature.
Endogenous peroxidase was quenched with 3% hydrogen
peroxide. The sections were incubated overnight at 4uCw i t h
1 mg/ml of anti-ST2 antibody (clone 9F8, Critical Diagnostics,
San Diego, USA), 1 mg/ml of anti-IL-33 antibody clone Nessy-1
(Enzo Life Sciences, New York, USA) or the same concentration
of a negative control mouse IgG antibody (Dako, Denmark). A
cytokeratin 7 antibody (Dako, Denmark) was used as a positive
control to label the syncytiotrophoblast (data not shown). A
biotin-free, tyramide signal amplification system was used (Dako,
Denmark) for detection, following the manufacturer’s instruc-
tions. The sections were finally counterstained with haematox-
ylin. Slides were examined using a Zeiss Axioskop brightfield
microscope with a Micropublisher 5MP RT camera.
Table 1. Clinical characteristics of women with pre-eclampsia, normal pregnant women and non-pregnant women (n=20).
Non-pregnant Normal Pregnant Pre-eclamptic
Age (years) 30.85 (5.38) 30.7 (5.79) 29.45 (5.53) n.s.
Nulliparity 14/20 14/20 14/20 n.s.
Gestation at sample (days) 238.12 (35.63) 241.45 (32.45) n.s.
Booking systolic BP (mmHg) 109.45 (13.04) 122.50 (14.36) p,0.05
Booking diastolic BP (mmHg) 65.90 (9.96) 77.15 (14.83) p,0.05
Max systolic BP (mmHg) 124.05 (9.64) 176.30 (17.54) p,0.0001
Max diastolic BP (mmHg) 75.21 (8.53) 113.65 (12.42) p,0.0001
Birthweight (g) 3408.45 (402.18) 2176.25 (1022.97) p,0.001
Data are shown as mean (+/2 standard deviation).
doi:10.1371/journal.pone.0024463.t001
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Placental tissue samples (normal (n=9) and pre-eclampsia
(n=9)) were lysed using HEPES lysis solution supplemented with
Complete Mini protease inhibitor cocktail (Roche, Germany).
Placental lysate protein concentrations were determined using a
BCA protein assay kit (Pierce, Thermo Scientific, Illinios, USA).
Proteins (30 mg) were resolved by 10% Bis-Tris Novex SDS-PAGE
(Invitrogen, Paisley, UK) and transferred to PVDF membrane.
Membranes were incubated for 45 minutes in blocking buffer
(PBS with 5% BLOTTO (Santa Cruz, California, USA) and 0.1%
Tween) at room temperature. The membranes were then
incubated overnight with the appropriate primary antibody at
4uC. Primary antibodies used were goat anti-ST2 (0.5 mg/ml)
(R&D Systems, Minneapolis, USA ), murine anti-IL-33 (0.1 mg/
ml) clone Nessy-1 (Enzo Life Sciences, New York, USA) or murine
anti-b-actin (0.155 mg/ml) (Abcam, Massachusetts, USA). Reac-
tions were visualised by incubating the membranes with the
appropriate anti-mouse or anti-goat secondary antibody conju-
gated to horseradish peroxidase (Dako, Denmark) for one hour
and detected using an enhanced chemiluminescence system
(Pierce, Thermo Scientific, Illinios, USA).
Placental perfusion model
To determine if IL-33 or sST2 are released from the villous
surface into the maternal circulation a modified dual placental
perfusion system was used as previously described [29]. Placentas
were obtained from normal pregnant, healthy women (n=8) or
women with pre-eclampsia (n=5) undergoing elective caesarean
section, without labor, and were processed immediately. The
maternal perfusates were centrifuged to remove cellular debris in a
Beckman J6-M centrifuge at 600 g for 10 min at 4uC, and aliquots
of the supernatants frozen at 280uC until analysed. sST2 was
measured in the perfusate by ELISA as described above, IL-33
was measured using a human IL-33 Duoset ELISA (R&D
Systems, Minneapolis, USA).
Release of sST2 from placenta explants
All placentas were from pregnant, healthy women undergoing
elective caesarean section, without labor, and were processed
immediately. Freshly delivered placentae (n=3) were first rinsed
in ice cold Hanks balanced salt solution and placed into a glove
box maintained at 8% O2. Placental pieces, cut from
undamaged lobules that appeared healthy, were rinsed in 8%
O2 equilibrated ice cold explant culture medium (DMEM
containing 10% foetal bovine serum (PAA Laboratories GmbH,
Austria), 1% antibiotic and antimycotic solution (Sigma Aldrich,
UK) and L-glutamine) before being placed into ice cold fresh
equilibrated explant culture medium. Placental pieces of
approximately 2 mm in diameter were then dissected and
distributed equally between Costar Netwell (24 mm diameter,
500 mm mesh) supports in 6-well plates containing 4 ml/well
equilibrated explant culture medium (10 explants/well). Pla-
cental explants were finally washed again with a medium
change before being incubated under conditions ‘normoxic’ for
trophoblast (8% O2/87% N2/5% CO2) [30] for 24 hours.
Explants were also treated with 100 ng/ml TNF-a or 100 ng/
ml IL-1b (Peprotech, NJ, U.S.A.) under normoxic conditions,
placed at 1% O2/94% N2/5% CO2 to stimulate hypoxic
conditions, or placed at 1% O2/94% N2/5% CO2 for 1 hour
before switching to 8% O2/87% N2/5% CO2 for 23 hours,
simulating hypoxia-reoxygenation conditions. After 24 hr the
explant supernatants were collected and centrifuged at 600 g for
10 min to remove cell debris. Explants were rinsed in PBS,
c o l l e c t e da n dl y s e di nH E P E Sl y s i sb u f f e rs u p p l e m e n t e dw i t h
Complete Mini protease inhibitor cocktail (Roche, Germany)
and protein concentration determined using a BCA Assay
(Pierce, Illinois, U.S.A.). The quantity of sST2 released from
Table 2. Clinical characteristics of women with pre-eclampsia and normal pregnant women (n=15) in the longitudinal study.
Non-pregnant Normal Pregnant Pre-eclamptic
Age (years) 28.60 (4.93) 28.00 (5.50) 27.93 (5.75) n.s.
Nulliparity 14/15 14/15 14/15 n.s.
Gestation at delivery (days) 282.00 (6.11) 250.50 (33.59) p,0.001
Booking systolic BP (mmHg) 109.80 (13.68) 115.67 (13.64) n.s.
Booking diastolic BP (mmHg) 65.53 (8.59) 70.07 (11.18) n.s.
Max systolic BP (mmHg) 125.89 (7.57) 160.33 (13.22) p,0.001
Max diastolic BP (mmHg) 78.93 (7.25) 107.13 (8.67) p,0.001
Birthweight (g) 3439.93 (495.84) 2792.79 (1107.13) n.s.
Data shown are mean (+/2 standard deviation).
doi:10.1371/journal.pone.0024463.t002
Table 3. Clinical characteristics of women with pre-eclampsia
and normal pregnant women (n=50).
Normal Pregnant Pre-eclamptic
Age (years) 31.43 (5.58) 30.80 (5.61) n.s.
Nulliparity 39/50 39/50 n.s.
Gestation at
sample (days)
231.6 (34.87) 223.1 (34.22) n.s.
Booking systolic
BP (mmHg)
105.7 (11.09) 120.9 (14.28) p,0.001
Booking diastolic
BP (mmHg)
64.53 (9.82) 73.68 (12.59) p,0.01
Max systolic BP
(mmHg)
125.8 (11.62) 175.80 (18.13) p,0.0001
Max diastolic
BP (mmHg)
77.56 (7.12) 125.30 (33.46) p,0.0001
Birthweight (g) 3392.73 (392.76) 1967.00 (1012.75) p,0.0001
Data are shown as mean (+/2 standard deviation).
doi:10.1371/journal.pone.0024463.t003
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of the total explants per condition. Supernatants were collected
and stored at 280uC for ELISA. Results were expressed as %
sST2 release from explants under varying conditions compared
to normoxia (100%). IL-33 was measured in the supernatants by
ELISA (R&D Systems).
Statistical analysis
Gaussian distribution of data was confirmed using a Kolmogor-
ovv-Smirnov test. For the longitudinal study, where the data were
normally distributed, a repeated measures ANOVA was used with
a Bonferroni post hoc test. For non-parametric longitudinal data a
Kruskal Wallace test was used with a Dunn’s post hoc test. To
assess the predictive value of sST2 for pre-eclampsia a ROC curve
was generated.Where paired data were shown to be normally
distributed, a paired t-test was performed. Non-parametric paired
data was analysed using a Wilcoxon matched pairs test. Non
matched data comparing non-pregnant to longitudinal data was
compared with an unpaired t test. Statistics were generated using
Prism and SPSS software. Values of p,0.05 were considered to be
statistically significant.
Results
There is no significant variation in circulating IL-33 in
women with normal or pre-eclamptic pregnancies
IL-33 serum levels were measured in 20 matched trios of
women with pre-eclampsia, normal pregnant women and non-
pregnant controls (Figure 1A). Despite a raised median value in
the pre-eclamptic women there were no significant differences
between groups. IL-33 was then measured in serum samples
taken in the first, second and third trimester from 15 women who
subsequently developed pre-eclampsia and 15 matched normal
pregnant controls. An additional sample taken at the time of pre-
eclampsia diagnosis was available for 13 of the women. There
were no differences in IL-33 levels throughout pregnancy in
women who went on to develop pre-eclampsia compared to
the normal pregnant controls, or during the active disease
(Figure 1B).
sST2 is increased in the third trimester of normal
pregnancy and is significantly elevated in pre-eclampsia
prior to the onset of clinical symptoms
Circulating sST2 was next measured in 20 matched trios of
women with pre-eclampsia, normal pregnant women and non-
pregnant controls. sST2 levels were significantly increased
(p,0.001) in women with pre-eclampsia (mean 85.89 ng/ml)
compared to normal pregnant (mean 25.20 ng/ml) and non-
pregnant women (mean 20.37 ng/ml) (Figure 2A). Plasma sST2
was measured in samples from normal pregnant and pre-eclamptic
women throughout each trimester of pregnancy, with an
additional sample taken at the time of diagnosis. There was a
significant increase in sST2 in the third trimester of normal
pregnancy (mean 34.87 ng/ml) compared to the first (mean
21.48 ng/ml) and second (mean 20.60 ng/ml) trimesters
(p,0.001) (Figure 2B). Similarly, sST2 levels increased as
pregnancy progressed, and levels were significantly higher in the
third trimester of pre-eclamptic pregnancies (mean 54.28 ng/ml)
compared to third trimester samples from normal pregnancies
(p,0.001), even before the onset of clinical symptoms. When
clinical symptoms were present sST2 levels were further increased
(mean 77.82 ng/ml). The predictive value of sST2 at the third
trimester sample time was assessed by generating a ROC curve,
giving an AUC of 0.813, the 95% confidence interval had a lower
bound of 0.642 and upper bound of 0.984. On average the women
(n=10) developed pre-eclampsia 20 days after this sample was
taken. No differences between non-pregnant samples and normal
pregnant first and second trimester samples were noted, however,
as expected, there was a significant increase in the third trimester
(p,0.001).
Thisstudy was then extended to a larger group of 50 women with
pre-eclampsia and matched normal pregnant women (Figure 3).
The statistically significant increase in circulating levels of sST2 in
the pre-eclampsia group was confirmed (p,0.001) (data not shown).
Within the pre-eclamptic patient group the diagnosis was made
between 22 weeks and 41 weeks gestation. sST2 levels were
therefore compared to gestational age in both groups. In normal
pregnancy circulating sST2 levels were strongly correlated with
gestational age (r=0.659, p,0.001) (Figure 3). In pre-eclampsia
Figure 1. Circulating IL-33 in pregnancy and pre-eclampsia. A) IL-33 was detected by ELISA in the serum from women with a diagnosis of pre-
eclampsia, matched controls who had a normal pregnancy and matched non-pregnant women (n=20). No significant differences in IL-33 were
identified. Bars represent median values. B) IL-33 was detected by ELISA in samples taken throughout pregnancy in women who developed pre-
eclampsia and matched controls who had an uncomplicated pregnancy (n=15). Blood samples were taken in each trimester of pregnancy (1, 2, 3)
and at the diagnosis of pre-eclampsia (PE), and compared to non-pregnant matched women. There were no significant differences throughout
pregnancy or between normal and pre-eclampsia pregnancies. Bars represent median values.
doi:10.1371/journal.pone.0024463.g001
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as even in early onset pre-eclampsia sST2 levels were high.
sST2 and IL-33 are expressed by both normal and pre-
eclampsia placentas
As circulating sST2 is increased in pregnancy, we speculated
that the placenta may be a source. Although significant changes to
circulating IL-33 were not detected throughout pregnancy it may
be a local mediator that is not detected systemically, therefore we
also investigated IL-33 expression. Immunoblotting showed the
presence of IL-33 and ST2 in lysates of all normal and pre-
eclampsia placental tissues studied (Figure 4A). Two forms of IL-
33 were detected; full length IL-33 (closed arrow) was identified in
all normal and pre-eclampsia placentas and the shorter cleaved
form was identified in several of the placentas (open arrow). All of
the normal and pre-eclamptic placentas expressed ST2. Densi-
tometry was performed to standardise protein expression to actin
quantity, no differences between normal and pre-eclamptic
placentas were detected (Figure 4B). Placental sections were then
analysed immunohistochemically to determine the cellular local-
isation of the IL-33 and ST2 (Figure 4C–H). Labelling for both
molecules was variable. IL-33 localised to the syncytiotrophoblast
and the chorionic villi. ST2 localised to some cells in the villous
stroma with staining of the syncytiotrophoblast. No differences in
staining profiles were seen between normal and pre-eclampsia
placentas. No specific staining was seen in IgG controls and the
positive control antibody (anti-Cytokeratin-7) strongly stained the
syncytiotrophoblast (data not shown).
The placenta may be the source of some of the sST2 in
pregnancy and pre-eclampsia
To determine whether sST2 and IL-33 can be released from the
placenta into the maternal circulation, supernatants from the
maternal side of placental perfusions (whereby the maternal blood
Figure 2. Circulating sST2 in pregnancy and pre-eclampsia.
A) sST2 was detected by ELISA in the plasma from women with a
diagnosis of pre-eclampsia, matched controls who had a normal
pregnancy and matched non-pregnant women (n=20). sST2 was
significantly raised in pre-eclampsia compared to normal pregnancy
(p,0.001). B) sST2 was detected by ELISA in samples taken throughout
pregnancy in women who developed pre-eclampsia and matched
controls who had an uncomplicated pregnancy (n=15). Blood samples
were takenin each trimester of pregnancy (1, 2, 3) andat the diagnosisof
pre-eclampsia (PE), and compared to non-pregnant matched women.
There is a significant increase in plasma sST2 in the third trimester of
normal pregnancy compared to the first or second trimester (p,0.001),
and compared to the non-pregnant group (p,0.001). sST2 was
significantly raised in pre-eclampsia compared to normal pregnancy
during the third trimester (p,0.01), prior to the onset of clinical
symptoms. Levels further increased when pre-eclampsia symptoms
presented (p,0.05). Bars represent mean values, *=p,0.05,**=p,0.01,
***=p,0.001. C) ROC curve analysis indicates sST2 levels in the third
trimestersample(n=10)arelikelytopredictpre-eclampsia(AUC=0.813).
doi:10.1371/journal.pone.0024463.g002
Figure 3. Comparison of sST2 levels to gestational age. A) sST2
was detected by ELISA in plasma from women with a diagnosis of pre-
eclampsia and matched controls who had a normal pregnancy (n=50).
In normal pregnancy sST2 levels increase towards term. In pre-
eclampsia sST2 levels are significantly increased compared to controls
(p,0.001). Differences in sST2 levels in normal and pre-eclampsia
pregnancies were more apparent in early onset disease.
doi:10.1371/journal.pone.0024463.g003
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vivo) from normal (n=8) and pre-eclampsia (n=5) placentas were
assayed. High levels of sST2 could be detected in all of the
perfusates analysed from both normal and pre-eclampsia placentas
(Figure 5A). IL-33 was detected by ELISA in the perfusate
(Figure 5B) from only one normal placenta. To ensure that the
ELISA is able to detect IL-33 in this system, and in the presence of
sST2, we pre-incubated recombinant IL-33 (from the ELISA
standards) with culture medium alone or maternal perfusion
samples known to contain sST2 for 16 hours prior to ELISA (data
not shown). IL-33 could still be detected under each of these
conditions, suggesting that neither the media nor sST2 prevent
detection by ELISA.
sST2 secretion from the placenta is increased under
conditions mimicking pre-eclampsia
Next we investigated placental release of sST2 and IL-33
changes when treated with pro-inflammatory cytokines, and
hypoxia or hypoxia/reoxygenation conditions. Placental explants
were treated for 24 hours with TNFa or IL-1b (100 ng/ml), sST2
secretion increased by 20.6 and 9.7% respectively (Figure 5C).
Explants cultured under hypoxic conditions (1% O2) released
31.6% less sST2 than explants under normoxic conditions (8%
O2). The greatest increase (37.9%) in sST2 levels was induced by
hypoxia/reperfusion conditions (1 hour at 1% O2 followed by
23 hours at 8% O2). IL-33 could not be detected in the any of the
explant supernatants.
Figure 4. Expression of IL-33 and sST2 by the placenta. A) IL-33 was detected by western blotting of placental lysates from normal and pre-
eclampsia placentas (n=9). Both the full length (closed arrow) and cleaved forms (open arrow) were detected. ST2 was detected in each of the
placental lysates. B) Densitometry of protein bands standardised to actin expression revealed no change in the levels of IL-33 nor sST2 between
normal and pre-eclamptic placentas. C–H) Expression of IL-33 and sST2 can be seen in by immunocytochemical analysis of both normal (n=3) and
pre-eclampsia (n=3) placentas (C-E and F-H show staining from two representative placentas respectively).
doi:10.1371/journal.pone.0024463.g004
sST2 and Pre-Eclampsia
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sST2 levels were significantly increased in the third trimester of
normal pregnancy and further increased in pre-eclampsia. These
increases were detectable prior to the onset of clinical symptoms.
Circulating sST2 is increased in a variety of conditions associated
with systemic inflammation (summarised in [7]). Pre-eclampsia, as
a systemic inflammatory disease secondary to an oxidatively
stressed placenta, can now be included in this list.
The third trimester placenta expresses ST2, this confirms the
previous report of Kumar et al (1997) [31]. Western blotting
identified ST2 in all of the placental lysates analysed, no
differences between groups were detected. Immunohistochemical
staining identified ST2 in the syncytiotrophoblast layer, suggesting
it could be secreted into the maternal circulation. Placental
secretion of sST2 was first confirmed using a placental perfusion
model. Perfusates from all of the normal and pre-eclampsia
placentas examined contained sST2, although it was not possible
to directly compare the concentrations of sST2 in each of the
perfusates - the placentas were from varying gestational ages and
the size of placental lobes perfused (and hence the area of
syncytiotrophoblast contacted) was variable. sST2 is also produced
by alveolar epithelial cells, cardiomyocytes and, to a lesser extent,
by brain and small bowel cells [7], therefore the placenta is
unlikely to be the sole source of sST2 in pregnant and pre-
eclamptic women. In cardiac conditions associated with ventric-
ular hypertrophy and remodelling (also a feature of pre-eclampsia
[32]) increased circulating levels of sST2 are derived from
cardiomyocytes activated by mechanical stress or pro-inflamma-
tory stimuli [20]. Strong clinical evidence implicates the
endothelium as an additional source [8], and ST2 is produced
by proliferating endothelium in vitro [33]. sST2 is also increased in
other conditions involving the endothelium such as Dengue Fever
[34] or sepsis [17]. Endothelial dysfunction, a well known feature
of pre-eclampsia [35] could also contribute to raised levels of sST2
in pre-eclampsia.
Placental explants from normal pregnancies also secreted
sST2, and levels were increased in response to pro-inflammatory
stimuli (IL-1b or TNF-a) or hypoxia-reoxygenation injury, both
of which are features of pre-eclamptic placentas [1]. In other cell
types sST2 secretion is stimulated by stress, particularly
inflammatory stresses [31], and has anti-inflammatory actions
[36] through its blockade of the danger signal delivered by IL-33.
We have previously shown that expression of ST2L is increased
on peripheral blood NK and NKT-like cells in pregnancy [37],
which suggested that these might be a target for its ligand IL-33
and contribute to the type 2 bias of normal pregnancy. The
production of sST2 may reflect the enhanced ‘type 1’
inflammatory environment of the disorder compared to normal
pregnancy, as sST2 acts as a decoy receptor for IL-33, competing
with membrane bound ST2L. Therefore, the very high levels of
circulating sST2 seen in pre-eclampsia would be predicted to
decrease IL-33 binding to its receptor, thereby contributing to the
type 1 bias seen in this disease.
Figure 5. The placenta releases sST2. sST2 (A) and IL-33 (B) were detected by ELISA in maternal side perfusate from an ex vivo of placental
perfusion model. Normal (n=8) and pre-eclampsia (PE) (n=5) placentas were perfused. sST2 could be identified in media from all of the normal and
pre-eclampsia placental perfusions, IL-33 could be identified in one sample from a normal pregnancy. Bars represent median values. C) Placental
explants release sST2, secretion was increased by treatment with TNFa and IL-1b (100 ng/ml) and hypoxia-reperfusion injury, and was decreased
under hypoxic conditions (n=3).
doi:10.1371/journal.pone.0024463.g005
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normal pregnant and non-pregnant women at any stage of
gestation. Endothelial cells and epithelial cells constitute major
sources in vivo [11,36] and here we show the placenta also
expresses IL-33. IL-33 does not have a signal peptide, so must be
secreted non-classical pathways, such as after cell necrosis as an
alarmin, or as a proinflammatory cytokine with a general role as
an amplifier of innate immune responses [13,38]. However, IL-33
also acts as an anti-inflammatory intracellular nuclear factor
through binding to, and inhibition of, NF-kB [39,40]. To what
extent these functions are relevant to the normal pregnancy and
the pathogenesis of pre-eclampsia remains to be elucidated.
Pre-eclampsia is thought to be caused by excessive release of
anti-angiogenic sFlt-1 (the soluble VEGF receptor) from the
oxidatively stressed placenta [41]. Angiogenesis is stimulated by,
and stimulates, inflammation [42]. In general VEGF and sFlt-1
are upregulated together with vascular inflammation. sFlt-1, acting
as a decoy receptor for VEGF, is anti-inflammatory, for example,
higher circulating levels are associated with enhanced survival in
experimental sepsis [43]. sST2 seems to be a second anti-
inflammatory factor produced by the placenta in excess amounts
during the course of pre-eclampsia. The links between the
mechanisms by which the release of these two factors is increased
in preeclampsia have yet to be clarified.
In summary this study shows for the first time that sST2
increases in the third trimester of normal pregnancy and that sST2
is significantly increased in pre-eclampsia probably secondary to
the systemic vascular inflammation of the disorder. In addition we
have shown that sST2 is raised in pregnancies destined to be
complicated by pre-eclampsia even prior to the onset of clinical
symptoms, which raises the possibility of its use as a novel
biomarker for the disease, perhaps independent from other
markers such as sFlt-1, endoglin and placental growth factor
[44]. We have shown that the origin of at least some sST2 in
pregnancy is the placenta and that a stressed placenta, as in pre-
eclampsia, secretes more sST2. The functional role of sST2 in
pregnancy and pre-eclampsia has yet to be established and is
under investigation.
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